Sodium Zirconium Cyclosilicate

How Does Sodium Zirconium Cyclosilicate Work?

Sodium zirconium cyclosilicate is an inorganic, non-absorbed zirconium silicate compound with a crystalline lattice structure containing size-selective micropores. These micropores are engineered to a specific size that preferentially captures potassium ions (K⁺). As the medication transits through the small and large intestines, it functions as a potassium trap—exchanging potassium for sodium (Na⁺) and hydrogen (H⁺) ions. The captured potassium cannot escape and is excreted in the feces, reducing the amount that is reabsorbed into the bloodstream.

Lokelma demonstrates more than 25-fold selectivity for potassium over divalent cations such as calcium (Ca²⁺) and magnesium (Mg²⁺), minimizing depletion of other essential electrolytes—an advantage over older polymer resin binders. The potassium-lowering effect begins within approximately 1 hour of the first dose, with a median time to normokalemia of about 2.2 hours in pharmacodynamic studies. In clinical trials, reductions of up to 1.28 mmol/L in serum potassium were achieved within 48 hours at the initial dosing regimen (10 g three times daily).

Because sodium zirconium cyclosilicate is not absorbed from the GI tract, zirconium concentrations in blood and urine are essentially undetectable in treated patients. The drug is not metabolized by the liver and does not interact through CYP450 enzyme pathways. Its primary pharmacological interaction is a transient increase in gastric pH after each dose, which can affect the absorption of other pH-sensitive oral medications taken simultaneously—which is why all other oral medications should be spaced at least 2 hours before or after each dose.

How Hard Is It to Find Sodium Zirconium Cyclosilicate (Lokelma) in Stock?

As of 2026, sodium zirconium cyclosilicate (Lokelma) is not listed on the FDA's official drug shortage database. AstraZeneca has maintained stable manufacturing and national supply since the drug's approval in 2018. However, patients frequently report difficulty locating it at their local retail pharmacies. This is a distribution and stocking challenge, not a supply crisis.

The main reasons for stocking gaps include: no FDA-approved generic (reducing pharmacy turnover incentives), high per-unit cost (~$1,043/month retail), specialty pharmacy routing requirements by many insurance plans, and low prescription volume at individual retail locations. Specialty pharmacies—including CVS Specialty, Walgreens Specialty, and hospital-affiliated outpatient pharmacies—are the most reliable sources. Mail-order pharmacy is another excellent option for ongoing refills.

To find Lokelma in stock near you without calling pharmacies yourself, medfinder calls pharmacies on your behalf and texts you a list of locations that have your medication in stock. This is particularly valuable for specialty medications like Lokelma that aren't carried everywhere.

Who Can Prescribe Sodium Zirconium Cyclosilicate (Lokelma)?

Sodium zirconium cyclosilicate (Lokelma) is not a controlled substance and carries no DEA scheduling restrictions. It can be prescribed by any licensed healthcare provider authorized to prescribe medications in their state, without special DEA registration or additional prescriber certification. Prescribers must monitor serum potassium levels appropriately to guide dosing.

Healthcare providers who commonly prescribe Lokelma include:

• Nephrologists — primary prescribers; manage CKD, dialysis, and chronic hyperkalemia
• Cardiologists — manage hyperkalemia in heart failure patients on spironolactone, ACE inhibitors, and ARBs
• Internal medicine physicians — manage hyperkalemia in inpatient and outpatient settings
• Primary care physicians (PCPs) — manage chronic hyperkalemia in patients with diabetes, hypertension, or early CKD
• Nurse practitioners (NPs) and physician assistants (PAs) — can prescribe Lokelma in all 50 states within their scope of practice
• Endocrinologists — manage hyperkalemia related to diabetic kidney disease

Telehealth availability: Because sodium zirconium cyclosilicate is not a controlled substance, it can be prescribed through telehealth in most states without requiring an in-person visit. Nephrology and cardiology telehealth platforms (e.g., Teladoc Health, MDLive) can evaluate and prescribe for hyperkalemia. Recent lab results showing serum potassium levels are typically required before prescribing.

Is Sodium Zirconium Cyclosilicate a Controlled Substance?

No. Sodium zirconium cyclosilicate (Lokelma) is not a controlled substance and is not scheduled by the DEA. It has no abuse or dependence potential and carries no DEA schedule classification. This means there are no special prescribing restrictions associated with its controlled substance status—it can be prescribed at any appointment, refilled as the prescriber deems appropriate, and can be prescribed via telehealth in all states without the limitations that apply to Schedule II–V substances.

Although Lokelma is not controlled, it does require a valid prescription from a licensed healthcare provider. The drug is available only by prescription because proper dosing requires monitoring of serum potassium levels through regular blood tests. Dosing must be adjusted based on lab values, and prescribing without appropriate clinical monitoring can lead to hypokalemia (dangerously low potassium) or failure to adequately control hyperkalemia.

Common Side Effects of Sodium Zirconium Cyclosilicate (Lokelma)

The most commonly reported adverse reactions in clinical trials of Lokelma include:

• Edema (fluid retention/swelling) — most common; typically mild to moderate; caused by the ~400 mg sodium content per 5 g dose; more common at 15 g/day doses and in patients with heart failure or kidney disease
• Hypokalemia (low potassium) — can occur if dose is too high, dietary intake drops, or illness causes reduced food/fluid intake; symptoms include muscle weakness, cramping, fatigue, palpitations

Serious side effects to monitor:

• Severe edema/fluid overload — worsening shortness of breath, rapid weight gain, significant leg swelling; particularly in heart failure patients; may require diuretic dose adjustment
• Severe hypokalemia — cardiac arrhythmias, severe muscle weakness; requires immediate medical attention and dose reduction or discontinuation
• GI motility complications — contraindicated in severe constipation, bowel obstruction, or fecal impaction; should be avoided in patients with abnormal post-operative bowel motility

Final Thoughts on Sodium Zirconium Cyclosilicate (Lokelma)

Sodium zirconium cyclosilicate (Lokelma) represents a meaningful advance in the management of hyperkalemia. Its rapid onset of action (within 1 hour), high selectivity for potassium, favorable tolerability profile, and strong clinical trial evidence in CKD, heart failure, and dialysis populations make it a first-line potassium binder for many patients in 2026. The drug's ability to enable continued RAAS inhibitor therapy—protecting kidney and heart function—adds significant clinical value beyond simple potassium lowering.

The practical challenge is access. With no generic available, Lokelma is expensive ($1,000+/month retail), not stocked at many retail pharmacies, and requires prior authorization on most insurance plans. Patients and providers who plan ahead—by routing prescriptions to specialty pharmacies, initiating prior authorization early, and enrolling in the AstraZeneca savings card—consistently have better experiences getting and staying on treatment.

If you're struggling to locate Lokelma at a pharmacy near you, medfinder can help. medfinder calls pharmacies in your area to check which ones have your medication in stock and texts you the results—removing the frustrating search process so you can focus on your health.